AI Image
How a Promising Pancreatic Cancer Drug Loses Its Punch
Newser • • health
Key Points:
- Daraxonrasib, approved in August, approximately doubles median survival time for advanced pancreatic cancer patients but typically loses effectiveness after about seven months.
- Researchers found that while the drug eliminates about half of cancer cells within two weeks, the remaining cells change in appearance and behavior, resembling cells more responsive to chemotherapy.
- Blood tests revealed that many tumors increase production of KRAS, the protein targeted by daraxonrasib, suggesting resistance mechanisms that diminish the drug's long-term efficacy.
- These insights indicate that combining daraxonrasib with other KRAS inhibitors or chemotherapy might prolong its therapeutic benefits for pancreatic cancer patients.
